Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Payables: 2022-2025

Historic Payables for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $5.9 million.

  • Stoke Therapeutics' Payables rose 136.26% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.9 million, marking a year-over-year increase of 45.38%. This contributed to the annual value of $2.5 million for FY2024, which is 47.37% up from last year.
  • As of Q3 2025, Stoke Therapeutics' Payables stood at $5.9 million, which was up 36.12% from $4.3 million recorded in Q2 2025.
  • Over the past 5 years, Stoke Therapeutics' Payables peaked at $5.9 million during Q3 2025, and registered a low of $766,000 during Q4 2022.
  • In the last 3 years, Stoke Therapeutics' Payables had a median value of $2.5 million in 2024 and averaged $3.1 million.
  • In the last 5 years, Stoke Therapeutics' Payables slumped by 56.80% in 2023 and then surged by 153.53% in 2024.
  • Quarterly analysis of 4 years shows Stoke Therapeutics' Payables stood at $766,000 in 2022, then soared by 121.28% to $1.7 million in 2023, then spiked by 47.37% to $2.5 million in 2024, then spiked by 136.26% to $5.9 million in 2025.
  • Its Payables was $5.9 million in Q3 2025, compared to $4.3 million in Q2 2025 and $2.2 million in Q1 2025.